Stock AnalizLifeStance Health Group, Inc. LFST
Medical/Nursing Services · IPO 2021 · data as of November 13, 2026
LifeStance Health Group, Inc. (LFST) is a healthcare company listed in the US with a market value of about $5.4B. In the twelve months to September 30, 2026 it had revenue of $1.7B and net income of $72M, a net margin of 4.3%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a P/E of 74.1, a price to free cash flow of 29.9, 5-year revenue growth of 46% a year, a 5-year average ROIC of -7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 63% below the current price.
Score: 1.8 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.7B | $1.4B | $1.3B | $1.1B | $860M | $668M | $213M |
| Net income | $72M | $10M | -$57M | -$186M | -$216M | -$307M | $6M |
| Free cash flow | $179M | $110M | $86M | -$57M | -$26M | -$85M | $3M |
| EPS (diluted) | $0.19 | $0.02 | $-0.15 | $-0.51 | $-0.61 | $-0.00 | — |
| Net margin | 4.3% | 0.7% | -4.6% | -17.6% | -25.1% | -46.0% | 2.7% |
| ROIC | — | 0.9% | -1.6% | -8.8% | -9.7% | -15.5% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $16.80, 19% above the current price; targets range from $12.00 to $20.00; the consensus rating is “Buy”; expected EPS is $0.40 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is LifeStance Health Group’s P/E ratio?
About 74.1, based on the last twelve months of diluted earnings per share (forward P/E about 33.3).
Is LifeStance Health Group stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 63% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does LifeStance Health Group pay a dividend?
Not currently.
Is LifeStance Health Group a good stock to buy?
We do not give buy or sell advice. LifeStance Health Group scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.